Elizabeth Arangies

Clinical Project Manager / Epidemiologist / Clinical Team Lead

Elizabeth Arangies

Clinical Project Manager / Epidemiologist / Clinical Team Lead

With over a decade of experience across Phase 2 – 4 clinical trials and epidemiological studies, Ms. Elizabeth Arangies is a skilled clinical research professional in the academic, CRO and federal markets.

After earning her Bachelor of Science in Genetics at the University of Cape Town, Ms. Arangies was awarded a Masters of Science in Epidemiology by the London School of Hygiene and Tropical Medicine, qualifications which uniquely prepare her to develop and implement infectious disease research studies.

Prior to joining Rho, Ms. Arangies has held positions in the areas of clinical monitoring, project leadership, as well as clinical study and site management at a large academic research center.

In addition to her work on large scale global clinical trials, Ms. Arangies has worked on protocol and study development, investigator-led studies, and FDA orphan drug program studies. Ms. Arangies has had therapeutic experience in infectious disease, autoimmune disease, cardiovascular, solid organ transplant, oncology and neurology studies.

With her unique understanding both within developed and developing countries, Ms. Arangies brings valuable insight into the design and implementation of global clinical studies. The majority of her research focus has been on infectious diseases, having worked on over 16 infectious disease studies in HIV, tuberculosis, multidrug-resistant tuberculosis, and acute bacterial skin and skin structure infections (methicillin resistant s. aureus). Ms. Arangies has also worked on antimicrobials (antibiotics and anti-infectives), chemotherapeutics, antiretroviral, and vaccine trials. These trials have been varied in design and complexity, and include Early Bactericidal Activity (EBA) in-patient studies (Phase 2), vaccine trials (Phase 2), anti-infective studies (Phase 3) and traditional clinical trials (Phase 2-3).

Ms. Arangies has worked on a number of studies in which the data has contributed to successful IND submissions. As the research project lead at a large academic site, Ms. Arangies oversaw the enrollment of multiple complex TB and HIV trials, contributing to the site’s high enrollment numbers through close relationships with local TB and HIV clinics in order to educate and inform the population about clinical research.

Her strong understanding of clinical trial management and delivery requirements has allowed her to successfully meet deliverables and lead teams throughout her career. Ms. Arangies responsibilities have included protocol development, site identification and selection efforts, management of the clinical team, development of site and monitor training tools, development of project management plans and clinical monitoring plans, and the successful delivery of operational timelines.

Why clinical research?

“Growing up in a part of Africa where the negative impact of disease, especially infectious diseases, is an inescapable reality, I was naturally drawn to research where I could potentially improve the lives of those around me. A career in clinical research was an opportunity for me to contribute to research efforts and indirectly have a positive impact on my community.”

Why infectious disease?

“Not only because of the unique challenges that infectious disease research presents, but because there is great potential to make a significant and positive impact when a new therapy or vaccine is proven to be effective. I am also fascinated by the mechanisms of bacterial and viral infections, as well as how the burden of a disease can be mitigated by both treatment and prevention measures.”

This is what drives Elizabeth:

“It takes an army of researchers, looking at multiple aspects of a disease and researching many different interventions, for a breakthrough to be made. We all want positive results in our studies, but unfortunately, we don’t always see the results we had hoped for. I strive to play a role in implementing well-designed research that will not only produce the answers we need, but also in the shortest time possible. For me, playing a small role in that ‘army’ of researchers, contributing to the body of scientific knowledge, that’s what drives me and makes what I do … well worth it.”